The Flow Cytometry Core Facility Experience - ELRIGelrig.org/downloads/fci14/PFC14-DDavies.pdf ·...

30
The Flow Cytometry Core Facility Experience Derek Davies London Research Ins�tute ELRIG Pharmaceu�cal Flow Cytometry 2014

Transcript of The Flow Cytometry Core Facility Experience - ELRIGelrig.org/downloads/fci14/PFC14-DDavies.pdf ·...

The  Flow  Cytometry  Core  Facility  Experience  

Derek  Davies  London  Research  Ins�tute  

ELRIG  Pharmaceu�cal  Flow  Cytometry  2014  

The  Flow  Cytometry  Core  Facility  Experience  

�  Establishment,  growth  and  success  �  Benefits  of  centralisa�on  �  Challenges  for  management  �  Metrics  of  success  �  Adding  value      

The image cannot be displayed. Your computer may not have enough memory to open the image, or the image may have been

the red x still appears, you may have to delete the image and then insert it again.

0 101 102 103RFP

0

101

102

103

GFP

0 200 400 600 800 1000Propidium Iodide

100

101

102

103

104

Anti-

phos

phoH

3

100 101 102 103 104

Annexin V-FITC

100

101

102

103

104

Pro

pidi

um Io

dide

ELRIG  Pharmaceu�cal  Flow  Cytometry  2014  

Why  is  (flow)  cytometry  important?  

0  

2000  

4000  

6000  

8000  

10000  

12000  

1   4   7   10   13   16   19   22   25   28   31   34   37   40  

Number  

Year  

Flow  cytometry  publica�ons  1975-­‐2013  

ELRIG  Pharmaceu�cal  Flow  Cytometry  2014  

Centralises  the  hardware   Centralises  the  exper�se  

Why  is  a  core  cytometry  facility  important?  

It’s  self  evident  but  do  we  want  to  get  there  and,  if  so,  how?  

ELRIG  Pharmaceu�cal  Flow  Cytometry  2014  

Let’s  talk  about  me…  

ELRIG  Pharmaceu�cal  Flow  Cytometry  2014  

Let’s  talk  about  me…  

�  Established  core  facility  �  Started  mid  1980’s  �  Strong  culture  of  development  �  Large  staff  level  �  Proac�ve  internally  �  Proac�ve  externally    �  Courses    �  Mee�ngs    �  Collabora�on  

       

ELRIG  Pharmaceu�cal  Flow  Cytometry  2014  

Incep�on………..…..Growth…………….….Maturity  

Star�ng  from  scratch  

ELRIG  Pharmaceu�cal  Flow  Cytometry  2014  

Staff  

Equipment  

This  is  the  growth  of  the  LRI  Lab,  1990…..  

ELRIG  Pharmaceu�cal  Flow  Cytometry  2014  

 Appropriate  staff  level  

The  same  old  user  level  

 Appropriate  hardware  level  

…  to  today  

ELRIG  Pharmaceu�cal  Flow  Cytometry  2014  

Idea   Product  

This  is  what  we  do…  

Advice  and  assay  design  

Training  

Cytometer  opera�on  

Analysis  and  interpreta�on  

Future  planning  

ELRIG  Pharmaceu�cal  Flow  Cytometry  2014  

Line  Manager   User  Group  

Core  Manager  

Budget  Control  

Service  Charges  

Technology  awareness  and  evalua�on  

Advice  to  Lab  Users  

Adver�sement  

Ancillary  services  

Technical  development  

Data  control  

User  training  and  supervision  

Cell  sorter  opera�on  

Analy�cal  cytometer  opera�on  

Supervision  and  career  development  

Facility  Staff  

User  Base  

This  is  what  we  do…  

�  Natural  resistance  to  change  

�  No  clear  benefit  

�  May  need  new  skills/techniques  

�  Self  interest  

�  Fear  of  the  unknown  

�  Perceived  as  a  risk  

How  can  we  go  about  this?  There  are  hurdles  to  overcome…  

ELRIG  Pharmaceu�cal  Flow  Cytometry  2014  

�  Process  is  never  passive,  all  par�es  take  an  ac�ve  role    �   Change  driven  internally    

�  Innova�on  �  Users  needs  �  Improvement  �  Efficiency  

 �  Change  driven  externally      

�  Regula�ons  �  Organisa�on  �  Equipment  obsolescence  

 

How  can  we  go  about  this?  There  are  hurdles  to  overcome…  

ELRIG  Pharmaceu�cal  Flow  Cytometry  2014  

•  Analy�cal  Technology:    What  is  needed  to  cover  Lab  remit?  •  Sor�ng  Technology:    Is  it  required?  If  so,  what?  •  Clinical  Applica�ons:    Will  flow  cytometry  technology  be  used  for  IVD  

•  Will  Lab  need  cer�fica�on?  CLP?  GLP?  GMP?  •  Future  Laboratory  Requirements:    Will  you  need  to  “grow”  the  facility?  Addi�onal  hardware?  New  technologies?  

What  should  the  Core  Lab  provide?  

How  can  we  go  about  this?  

ELRIG  Pharmaceu�cal  Flow  Cytometry  2014  

•  General  Laboratory  environment  /  Health  and  Safety    

•  Business  planning  

•  Opera�onal  issues    

•  Staffing  and  staff  reten�on  

Not  all  considera�ons  are  cytometry-­‐related  

How  can  we  go  about  this?  

ELRIG  Pharmaceu�cal  Flow  Cytometry  2014  

�  Direct  funding  �  Own  grant  wri�ng  

�  Fee  for  service      �  PAYG  

   �  Contracted  

Where  does  funding  come  from?    

ELRIG  Pharmaceu�cal  Flow  Cytometry  2014  

User  Support:    Training  and  supervision  of  Users    

  Hands-­‐on  support  for  new  users        Support  for  Experienced  Users  -­‐  Advanced  Data  Acquisi�on  -­‐  Advanced  Troubleshoo�ng    

  Experimental  Design  Consulta�on  -­‐    Basic  Sample  Prepara�on  -­‐  Fluorescent  Reagent  Choice  -­‐  Experimental  analysis  

 

Tasks  performed  by  Staff    

ELRIG  Pharmaceu�cal  Flow  Cytometry  2014  

�  Self  evalua�on  –  do  we  provide  what  users  want?  �  How  accessible  are  the  services?  �  How  welcoming  is  the  environment?  �  Partners  not  customers  �  Add  value  �  Teaching  important  as  it  expands  knowledge    

Opera�onal  considera�ons  

Constant  monitoring  of  service  provision  

ELRIG  Pharmaceu�cal  Flow  Cytometry  2014  

�  Be  efficient  (and  make  sure  efficiencies  are  seen)  �  Staff  development  and  reten�on  �  Ensure  quality  �  Plan  for  the  future  �  Re-­‐invest  �  Open  door  policy    

Opera�onal  considera�ons  

Constant  monitoring  of  service  provision  

ELRIG  Pharmaceu�cal  Flow  Cytometry  2014  

�  Robust  research  �  New  and  emerging  technologies  �  R&D  

Opera�onal  considera�ons  

Constant  monitoring  of  service  provision  

Mission  statement  and  vision  “Cu�ng  edge  technology  and  development,  integra�ng  with,  and  adding  value  to,  research.”    

Research  is  a  risky  business  –  need  to  manage  risk  

ELRIG  Pharmaceu�cal  Flow  Cytometry  2014  

Usage  tracking:  

0

50

100

150

200

250

300

350

400

450

500

1 3 5 7 9 11 13 15 17 19 21 23 25 27 29 31 33 35 37 39 41 43 45 47 49 51 53 55 57

Month

Hours

Plateau  indicates  max  capacity  or  max  usage  

More  machines  or  more  users!  

Metrics  of  success  

ELRIG  Pharmaceu�cal  Flow  Cytometry  2014  

Sorter  2     Sorter  3    

0 5 10 15 20 25

Phenotyping: Thymo

Phenotyping: Cultured cells

Phenotyping: B/T cells

Phenotyping: Other

Fluorescent Proteins

Asceptic Sorting

Sorting for microarray

Sorting for RNA

DNA analysis

Apoptosis Analysis

BrdU Analysis

Development

Usage  can  show  when  new  equipment  needed  and  allows  targe�ng    of  the  right  people.  

0

20

40

60

80

100

120

1 9 17 25 33 41 49 57 65 73 81 89 97 105 113 121 129 137 145 153 161 169 177 185

Metrics  of  success  

ELRIG  Pharmaceu�cal  Flow  Cytometry  2014  

Surveys  

 What  the  facility  does  well  

 What  it  does  not  so  well  

 Use  several  methods  

     

 Talk  to  users!  

   

Customer  sa�sfac�on  

Keep  up  the  good  work  

ELRIG  Pharmaceu�cal  Flow  Cytometry  2014  

Interac�on  with  users  

 Go  to  Lab  mee�ngs  and  seminars  

 Be  accessible,  go  walkabout,  drink  coffee  

 Become  involved  with  the  science  

 

Interac�on  with  other  cores  

 Go  to  conferences  with  cytometry  content  

 Business  cards  with  mul�ple  contacts  

 Core  Heads  Group  especially  allied  technologies  

Keep  up  the  good  work  

ELRIG  Pharmaceu�cal  Flow  Cytometry  2014  

Cer�fica�on    SOPs    ISO9001    ICCE    ISAC  SRL  

 GxP  –  21CFR  

   

 

 

 

Keep  up  the  good  work  

ELRIG  Pharmaceu�cal  Flow  Cytometry  2014  

Cancer    Chromosomes    DNA  replica�on    DNA  repair    Vascular  Biology    Cell  signalling    Stem  Cells    Immunity    Structural  Biology  

Human  Health    Developmental  Biology    Neurobiology      Immunity  and  infec�on    Immunoregula�on    Mycobacteria    Parasitology    Physiology      Virology  

Drug  development  HTS  Chemistry  Others?    

Challenges  for  the  future  

ELRIG  Pharmaceu�cal  Flow  Cytometry  2014  

New  hardware  

Be�er  training  Be�er  educa�on  

New  technology  

Challenges  for  the  future  

ELRIG  Pharmaceu�cal  Flow  Cytometry  2014  

Challenges  for  the  future  

ELRIG  Pharmaceu�cal  Flow  Cytometry  2014  

Summary  

What  can  centralisa�on  add?  

�  The  ability  to  get  moving  using  established  technology  �  The  ability  to  introduce  techniques  using  experienced  staff  who  understand  the  technology  

�  Be  at  the  forefront  of  newer  developments  by  being  seen  as  expert  by  manufacturers  

�  Introduc�on  and  awareness  of  current  Best  Prac�ces  

ELRIG  Pharmaceu�cal  Flow  Cytometry  2014  

Summary  

[email protected]  

ELRIG  Pharmaceu�cal  Flow  Cytometry  2014